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Abstract
The mechanism of massive intravascular haemolysis occurring during the treatment of malaria infection resulting in
haemoglobinuria, commonly known as blackwater fever (BWF), remains unknown. BWF is most often seen in those
with severe malaria treated with amino-alcohol drugs, including quinine, mefloquine and halofantrine. The potential
for drugs containing artemisinins, chloroquine or piperaquine to cause oxidant haemolysis is believed to be much
lower, particularly during treatment of uncomplicated malaria. Here is an unusual case of BWF, which developed on
day 2 of treatment for uncomplicated Plasmodium falciparum infection with dihydroartemisinin-piperaquine
(DHA-PIP) with documented evidence of concomitant seropositivity for Chikungunya infection.
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Background
Haemoglobinuria is a feature of complicated malaria
syndromes as defined by the World Health Organization
(WHO) [1]. Blackwater fever (BWF) is due to massive
haemolysis of red blood cells in the blood stream with
subsequent haemoglobinuria, anaemia, often accompan-
ied by renal failure. By published reports, BWF occurs
most often in Plasmodium falciparum infections, but
has also been documented in Plasmodium vivax, Plas-
modium malariae and mixed infections [2-6]. Though
the exact mechanisms involved remain unclear, several
factors appear associated with BWF such as G6PD defi-
ciency, severe malaria infection, treatment of malaria
with amino-alcohol drugs, particularly quinine, and pres-
ence of other viral or bacterial infections [3,4,7].
Case presentation
A 43-year old male Cambodian farmer was screened and
enrolled on 21 July 2013 to participate in a clinical trial
evaluating the efficacy of a course of dihydroartemisinin-
piperaquine (360 mg/2880 mg) divided over three days
for uncomplicated P. falciparum malaria with or without
a single dose of primaquine 45 mg to prevent transmis-
sion of gametocytes (NCT 01849640). During the three
days before enrollment, he reported experiencing mild
fever, chills and fatigue, and self-treated with paraceta-
mol and ampicillin. On the day of enrollment, he was
found to have P. falciparum infection with 31,218 para-
sites per μl on peripheral blood smear at an outside
medical facility, and was referred to the study team. He
denied having taken any anti-malarial or traditional
herbal medications, but he did inform the study team
that he has been consuming 1–2 cans per day of an en-
ergy drink containing taurine, caffeine, and B vitamins
for the past year. He reported no chronic underlying ill-
nesses. He had suffered four malaria episodes since 2010
which were variously treated with chloroquine, artesu-
nate and mefloquine, but reported no prior history of
adverse reactions to anti-malarials or history of BWF.
Initial vital signs included a heart rate of 70, blood
pressure of 108/69 mmHg, and a tympanic temperature
of 38.1°C. He was not ill-appearing and had no jaundice,
icterus, conjunctival pallor or rash. The remainder of the
physical examination was unremarkable, including a
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galy. Urine was light tea coloured. Initial laboratory as-
sessment revealed mild anaemia (Hb, 10.3 g/dl and
HCT, 30.3%), low serum calcium (6.7 mg/dl), and nor-
mal serum creatinine (0.92 mg/dL). His G6PD activity
was normal (9.8 U/g Hb, normal range 4.6-13.5 U/g Hb),
and serial 10-second surface EKG tracings were normal,
with an average manual QTcF of 444 ms.
Twenty-eight hours following admission, after com-
pleting the first two doses of DHA-PIP, he was observed
to have dark ‘coca-cola’ coloured urine. His fever was
still present and new signs and symptoms developed in-
cluding pallor, dizziness, fatigue, anorexia and semi-
watery diarrhea with abdominal pain in the right lower
quadrant. Acute renal injury with an increase in serum
creatinine from 0.92 to 1.7 g/dL, along with a decline in
haemoglobin to 8.1 g/dL (21% decrease from baseline),
was observed. He was switched to intravenous artemether
(160 mg on day 1, 80 mg per day on days 2–5) for severe
malaria with blackwater fever. He continued to have an
appropriate response to anti-malarial therapy, with a de-
cline in peripheral parasitaemia to 286 parasites/μlw i t h i n
48 hours, and was smear negative by day 5 (Table 1).
Primaquine therapy was withheld.
On day 3, he continued to experience fatigue, anorexia
and jaundice. Serum creatinine continued to rise to a
maximum 3.79 g/dL on D9 although there were never
any electrolyte abnormalities. Other laboratory abnor-
malities included maximum indirect hyperbilirubinaemia
of 2.95 mg/dL, aspartate aminotransferase of 265 U/L,
and alkaline phosphatase of 163 U/L peaking on days 2,
5 and 7 respectively. A single unit blood transfusion was
given on day 4 for a continued low haemoglobin level
(8.4 g/dL) with levels thereafter remaining stable at
approximately 8.0 g/dL (7.7-8.8 g/dL). Serology for co-
infections was negative for IgM against leptospira, all four
dengue serotypes, scrub typhus, HIV and Salmonella
typhi, but positive for reactive IgM against chikun-
gunya virus. Urine colour normalized on day 7, and serum
creatinine returned to 1.8 mg/dL within 4 weeks, and
there was normal to high urine output throughout the
admission.
Discussion
There are not well-defined predictive risk factors for
BWF, and the syndrome is often diagnosed only after
malaria patients undergoing treatment are noted to have
dark-coloured urine. The mechanisms of BWF remain
unknown though it has been associated with low levels
of P. falciparum parasitaemia, partial malaria immunity,
G6PD deficiency, and treatment with amino-alcohol
drugs [2-5,7]. In this case, the patient had no risk factors
above for developing BWF and had been treated un-
eventfully for malaria on four prior occasions with vari-
ous drugs including mefloquine over the past three
years. A history of multiple malaria infections are associ-
ated with BWF, and this, along with a likely concomitant
partial immunity, seems to have been his only risk factor
[2,4,5,8]. The patient seemed to have a mild case of
BWF as he had stable vital signs, few signs/symptoms,
and electrolytes within normal limits suggesting pre-
served renal function despite acute injury. This is similar
to a recent prospective case series in nearby Vietnam,
which reported overall mild severity and better out-
comes [1,2], but in contrast to previous reports of high
mortality with a 26% case fatality rates in European pa-
tients [9-11] and 23% in African patients [12] with more
severe malaria.
Table 1 Key laboratory values
Parameters (normal values) D1 D2 D3 D5 D7 D9 D10 W2 W3 W4 W5
WBC 10
3/μL (4.0-10.0) 3.0 4.3 4.54 5.49 6.5 7.3 - 6.1 - 5.3 5.3
Blood smear (parasites/μl) 31,218 4,050 286 Neg. --- - - Neg Neg
HB g/dL (13–18) 10.3 8.1 8.4 7.9 8.8 8.5 - 7.7 - 8.3 8.2
PLT 10
3/μL (140–450) 71 68 70 113 215 283 - 347 - 264 193
Cr. mg/dL (0.8-1.3) 0.92 1.7 1.8 2.71 2.90 3.79 3.29 2.9 2.21 1.8 -
BUN mg/dL (7–18) 20.5 25.4 27.85 36.91 23.74 23.0 19.7 19.8 20.2 16.2 -
AST IU/dL (15–37) 43.6 261 249 265 111 58.0 - 36.7 - - -
Tot. bil. mg/dL (0–1.0) 0.818 2.95 2.2 2.1 0.809 0.595 - 0.5 - - -
Dir. bil. mg/dL (0.0-0.5) - - 0.2 0.3 - - - - - - -
K+mEq/L (3.5-5.1) 3.68 3.93 3.7 3.8 3.95 4.34 4.29 4.1 3.74 3.39 -
Na+mEq/L (136–148) 130 142
CHIKV (IgM) pos.
WBC; white blood cell (10
3/μL). HB; haemoglobin (g/dL). PLT; platelet (10
3/μ), Cr; serum creatinine (mg/dL). BUN; blood urea nitrogen (mg/dL). AST; aspartate
amino transferase (IU/dL). Tot. bil.; serum total bilirubin (mg/dL). Dir.bil.; serum direct bilirubin (mg/dL). K+; serum potassium (mEq/L). Na+; serum sodium (mEq/L).
CHIKV (IgM); Chikungunya virus (Immunoglobulin M). pos; positive.
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malaria who developed BWF after administration of
DHA-PIP. BWF is classically associated with the amino-
alcohols quinine, mefloquine and halofantrine of which
quinine is the most common culprit. Since chloroquine
was introduced after World War II supplanting quinine
as first-line treatment of uncomplicated malaria, there
has been an observed decrease in BWF [1]. A recent re-
port suggested that metabolism of quinine by the cyto-
chrome P450 3A4 enzyme may be responsible for
increasing oxidative stress within erythrocytes, making
these cells more vulnerable to haemolysis in those with
m a l a r i aa n d / o rG 6 P Dd e f i c i e n c y[ 1 3 ] .T h er o l eo fa r t e m i s i -
nin compounds in such potential oxidant acute haemolysis
remains poorly understood [14]. Parenteral artesunate was
associated with low, but comparable, rates of BWF com-
pared to quinine in a large trial of paediatric patients
with severe malaria (0.7% versus 1.2% respectively) [6].
Dihydroartemisinin-piperaquine (DHA-PIP) is a combin-
ation of a potent, rapid acting artemisinin derivative, com-
bined with a long-acting 4-aminoquinoline (bis-quinoline),
similar to chloroquine. Neither chloroquine, nor its more
recently introduced analogue piperaquine, have been asso-
ciated with blackwater fever [1,15]. There has been one
published report of a patient who developed BWF three
weeks after stopping prophylactic chloroquine and progua-
nil [3]. The dihydroartemisinin component contains a
highly active endoperoxide bridge and like artesunate, may
also be capable of inducing oxidant haemolysis, but has
not yet been reported to be a cause of blackwater fever
[14]. The patient reported consuming daily doses of tau-
rine, which is involved in many crucial physiological pro-
cesses [16]. However, its role is not clearly understood and
the influence of high taurine doses is uncertain. There has
so far been no evidence to implicate long-term ingestion of
taurine as a risk factor for haemolysis, though synthetic
taurine is obtained from isoethionic acid (2-hydroxyetha-
nesulfonic acid), an oxidant haemolytic.
In this case, the patient did have serologic evidence of
Chikungunya infection, but he lacked classic findings of
Chikungunya including arthritis, arthralgia, petechiae or
maculopapular rash. In a 2001 study by Bruneel et al.
[5] five of eight BWF patients were found to be co-
infected with viral infections including hepatitis C, B
and Epstein-Barr virus. However, these co-infection have
yet to be proven as significant factors influencing the
haemolytic potential of BWF [17]. The strong temporal
association here of administration of DHA-piperaquine
and onset of haemolysis and haemoglobinuria suggests
that clinicians treating uncomplicated malaria patients
with DHA-piperaquine, and likely other combinations
containing artemisinin derivatives, should be aware of
the rare possibility for development of blackwater fever
during or shortly after therapy.
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